Open Nav

Thomas Kelleher, PhD


Xylome Corporation

Current CEO of Xylome, formerly with Amgen, Cubist and Novo Nordisk. Tom has a 35+year career bringing biopharmaceuticals to market at large and startup biopharmaceutical companies. He was the lead inventor of the current commercial Cubicin commercial process, a $1.2billion/yr antibiotic of last resort, which was approved in 2003.

This speaker's sessions:

  • Xylome
  • Thursday, October 18
  • 11:30 AM - 11:45 AM